[P51] Poster Session 51　Head and Neck Cancer（Miscellaneous）

[P51-5] A phase 3 trial of xevinapant + concurrent chemoradiotherapy（CRT）for locally advanced head and neck cancer

^○Makoto Tahara¹, Ezra Cohen², Christopher Nutting³, Lisa Licitra^4,9, Barbara Burtness^5,10, Jonathan Schoenfeld⁶, Omar Mokhtar⁷, Florilene Bouisset⁷, Heidi Nauwelaerts⁷, Yulia Urfer⁷, Claudio Zanna⁷, Jean Bourhis⁸ (1.Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 2.University of California, 3.Royal Marsden NHS Foundation Trust, 4.Fondazione IRCCS Istituto Nazionale dei Tumori, 5.Yale School of Medicine, 6.Dana-Farber Cancer Institute, 7.Debiopharm International SA, 8.Centre Hospitalier Universitaire Vaudois, 9.University of Milan, 10.Yale Cancer Center)